3/4
08:01 am
cldx
Celldex Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Celldex Therapeutics to Present at Upcoming Investor Conferences
3/3
10:06 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $42.00 to $36.00. They now have a "neutral" rating on the stock.
Medium
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $42.00 to $36.00. They now have a "neutral" rating on the stock.
3/3
08:01 am
cldx
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
High
Report
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
3/1
07:07 pm
cldx
Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]
Medium
Report
Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]
3/1
12:45 pm
cldx
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Medium
Report
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
2/28
08:13 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
2/27
07:19 pm
cldx
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
2/27
05:49 pm
cldx
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/27
04:01 pm
cldx
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Low
Report
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
2/13
08:08 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $44.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $44.00 price target on the stock.
1/29
09:59 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Medium
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
1/21
12:28 pm
cldx
ACTG Launches Second HIV Cure Clinical Trial in Africa [Yahoo! Finance]
Neutral
Report
ACTG Launches Second HIV Cure Clinical Trial in Africa [Yahoo! Finance]
1/2
08:42 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
12/19
12:17 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
12/19
08:01 am
cldx
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Low
Report
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis